Mr Jake Nunn

KANDO id: 7967

Bio

Jake joined NEA in 2006 as a Partner. He focuses on later-stage specialty pharmaceuticals, biotechnology and medical device investments and manages a number of NEA's public investments in healthcare. Jake is a Director of Dermira (Nasdaq: DERM), Hyperion Therapeutics (Nasdaq: HPTX), Trevena, Inc. (Nasdaq: TRVN), and TriVascular (Nasdaq:TRIV). He previously was a Director of Aciex Therapeutics (sold to Nicox SA) and Transcept Pharmaceuticals (merged with Paratek Pharmaceuticals). Jake worked at MPM Capital as a Partner with the MPM BioEquities Fund, where he specialized in public, PIPE and mezzanine-stage life sciences investing. Previously, he was a healthcare research analyst and portfolio manager at Franklin Templeton Investments. Jake was also an investment banker with Alex. Brown & Sons. He received an MBA from the Stanford Graduate School of Business and an AB in Economics from Dartmouth College. Jake holds the Chartered Financial Analyst designation, and is a member of the CFA Society of San Francisco.

Career


New Enterprise Associates Inc

Global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies.
Partner (past)
Focus areas: Healthcare, Biopharma, Devices.
From
Email: [email protected]

Education